Publications by authors named "Shannon A Ferrante"

Claim this Profile
C
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors.
Philip J Mease, Shannon A Ferrante, Natalie J Shiff, Timothy P Fitzgerald, Soumya D Chakravarty

Adv Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial and Ethnic Disparities in Treatment Initiation Among Patients with Newly Diagnosed Psoriatic Arthritis: A Retrospective Medicaid Claims Database Study.
Aarti A Patel, Shannon Allen Ferrante, Iris Lin, Alex Z Fu, Alicia K Campbell

Rheumatol Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals.
Chang Xu, Shannon A Ferrante, Timothy Fitzgerald, Christopher D Pericone, Bingcao Wu

J Manag Care Spec Pharm· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Thibaud Prawitz, Rakesh Popat, Attaya Suvannasankha, Grammati Sarri, Rachel Hughes, Shannon Allen Ferrante

Adv Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison.
Sam Keeping, Elise Wu, Keith Chan, Ali Mojebi, Shannon Allen Ferrante

Expert Rev Hematol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Yock Young Dan, Shannon A Ferrante, Elamin H Elbasha, Tun-Ying Hsu

Antivir Ther· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Kostas Athanasakis, Shannon Allen Ferrante, Ilias-Ioannis Kyriopoulos, Ioannis Petrakis, Mary Hill

Clin Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.
Jagpreet Chhatwal, Shannon A Ferrante, Cliff Brass, Antoine C El Khoury, Margaret Burroughs

Value Health· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary.
Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury, Elamin Elbasha

J Health Econ Outcomes Res· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Shannon Allen Ferrante, Jagpreet Chhatwal, Clifford A Brass, Antoine C El Khoury, Fred Poordad

BMC Infect Dis· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Elamin H Elbasha, Jagpreet Chhatwal, Shannon A Ferrante, Antoine C El Khoury, Pedro A Laires

Appl Health Econ Health Policy· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Karl J Krobot, Shannon Allen Ferrante, Michael J Davies, Thomas Seck, Gary E Meininger

Curr Med Res Opin· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study.
Timo Vesikari, Aino Karvonen, Shannon Allen Ferrante, Max Ciarlet

Eur J Pediatr· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine.
Timo Vesikari, Aino Karvonen, Shannon Allen Ferrante, Barbara J Kuter, Max Ciarlet

Pediatr Infect Dis J· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis